Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Platform trials.
Roustit M, Demarcq O, Laporte S, Barthélémy P, Chassany O, Cucherat M, Demotes J, Diebolt V, Espérou H, Fouret C, Galaup A, Gambotti L, Gourio C, Guérin A, Labruyère C, Paoletti X, Porcher R, Simon T, Varoqueaux N. Roustit M, et al. Among authors: paoletti x. Therapie. 2023 Jan-Feb;78(1):29-38. doi: 10.1016/j.therap.2022.12.003. Epub 2022 Dec 5. Therapie. 2023. PMID: 36529559 Free PMC article.
Les essais plateformes.
Roustit M, Demarcq O, Laporte S, Barthélémy P, Chassany O, Cucherat M, Demotes J, Diebolt V, Espérou H, Fouret C, Galaup A, Gambotti L, Gourio C, Guérin A, Labruyère C, Paoletti X, Porcher R, Simon T, Varoqueaux N. Roustit M, et al. Among authors: paoletti x. Therapie. 2023 Jan-Feb;78(1):19-28. doi: 10.1016/j.therap.2022.11.011. Epub 2022 Dec 5. Therapie. 2023. PMID: 36581520 Free PMC article. French.
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial.
Lebret T, Paoletti X, Pignot G, Roumiguié M, Colombel M, Savareux L, Verhoest G, Guy L, Rigaud J, De Vergie S, Poinas G, Droupy S, Kleinclauss F, Courtade-Saïdi M, Piaton E, Radulescu C, Rioux-Leclercq N, Kandel-Aznar C, Renaudin K, Cochand-Priollet B, Allory Y, Nivet S, Rouprêt M. Lebret T, et al. Among authors: paoletti x. World J Urol. 2023 Sep;41(9):2381-2388. doi: 10.1007/s00345-023-04519-4. Epub 2023 Jul 22. World J Urol. 2023. PMID: 37480491 Free PMC article.
Pan-cancer evaluation of tumor-infiltrating lymphocytes and programmed cell death protein ligand-1 in metastatic biopsies and matched primary tumors.
El Beaino Z, Dupain C, Marret G, Paoletti X, Fuhrmann L, Martinat C, Allory Y, Halladjian M, Bièche I, Le Tourneau C, Kamal M, Vincent-Salomon A. El Beaino Z, et al. Among authors: paoletti x. J Pathol. 2024 Oct;264(2):186-196. doi: 10.1002/path.6334. Epub 2024 Jul 29. J Pathol. 2024. PMID: 39072750 Clinical Trial.
Stakeholder Perspectives on Randomized Clinical Trials for Children With Poor-Prognosis Cancers.
Bird N, Scobie N, Berlanga P, Blanc P, Buenger V, Campbell-Hewson Q, Casanova M, DuBois S, Glade Bender J, Graham A, Heenen D, Ip-Toma C, Ludwinski D, Moreno L, Neuberg D, Palmer A, Paoletti X, Plieger-van Solkema W, Reaman G, de Rojas T, Rossig C, Schiel A, Wakeling S, Vassal G, Pearson A, Knox L. Bird N, et al. Among authors: paoletti x. JAMA Netw Open. 2024 Dec 2;7(12):e2449239. doi: 10.1001/jamanetworkopen.2024.49239. JAMA Netw Open. 2024. PMID: 39641924 Free article.
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.
Kabirian R, Tredan O, Marmé F, Paoletti X, Eberst L, Lebreton C, De La Motte Rouge T, Sabatier R, Angelergues A, Fabbro M, Van Gorp T, Mansi L, Gladieff L, Kaczmarek E, Alexandre J, Grellety T, Favier L, Welz J, Frenel JS, Leary A. Kabirian R, et al. Among authors: paoletti x. Future Oncol. 2024;20(35):2699-2708. doi: 10.1080/14796694.2024.2386922. Epub 2024 Aug 19. Future Oncol. 2024. PMID: 39155847 Free PMC article.
Precision cancer medicine platform trials: Concepts and design of AcSé-ESMART.
Geoerger B, Bautista F, André N, Berlanga P, Gatz SA, Marshall LV, Rubino J, Archambaud B, Marchais A, Rubio-San-Simón A, Ducassou S, Zwaan CM, Casanova M, Nysom K, Pellegrino S, Hoog-Labouret N, Buzyn A, Blanc P, Paoletti X, Vassal G. Geoerger B, et al. Among authors: paoletti x. Eur J Cancer. 2024 Sep;208:114201. doi: 10.1016/j.ejca.2024.114201. Epub 2024 Jul 14. Eur J Cancer. 2024. PMID: 39018630 Review.
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer.
Bautista F, Verdú-Amorós J, Geoerger B, Rubio-San-Simón A, Paoletti X, Zwaan CM, Casanova M, Marshall LV, Carceller F, Doz F, Lecinse C, Vassal G, Pearson ADJ, Kearns P, Moreno L; Innovative Therapies For Children With Cancer Consortium. Bautista F, et al. Among authors: paoletti x. J Clin Oncol. 2024 Jul 20;42(21):2516-2526. doi: 10.1200/JCO.23.01237. Epub 2024 May 14. J Clin Oncol. 2024. PMID: 38743911
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
Tjokrowidjaja A, Friedlander ML, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Lord SJ, Scott CL, Goble S, York W, Lee CK; Gynecologic Cancer Intergroup Meta-Analysis Committee. Tjokrowidjaja A, et al. J Clin Oncol. 2024 Apr 10;42(11):1301-1310. doi: 10.1200/JCO.23.01182. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215359
165 results